Ken Griffin Precigen, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $1.75 $21,336 - $29,400	16,800 Added 27.36%	78,200 $123,000
Q1 2024 May 15, 2024	BUY	$1.21 - $1.75 $57,354 - $82,950	47,400 Added 338.57%	61,400 $89,000
Q4 2023 Feb 14, 2024	BUY	$0.89 - $1.41 $356 - $564	400 Added 2.94%	14,000 $18,000
Q3 2023 Nov 14, 2023	SELL	$1.08 - $1.85 $32,400 - $55,500	-30,000 Reduced 68.81%	13,600 $19,000
Q2 2023 Aug 14, 2023	BUY	$0.96 - $1.4 $2,976 - $4,340	3,100 Added 7.65%	43,600 $50,000
Q1 2023 May 15, 2023	SELL	$0.88 - $2.19 $35,024 - $87,162	-39,800 Reduced 49.56%	40,500 $42,000
Q4 2022 Feb 14, 2023	BUY	$1.27 - $2.26 $4,699 - $8,362	3,700 Added 4.83%	80,300 $122,000
Q3 2022 Nov 14, 2022	BUY	$1.41 - $2.79 $20,586 - $40,734	14,600 Added 23.55%	76,600 $162,000

144

146M

292K

53.8K

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $198M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.